Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers (Tables)

v3.22.2
Revenue from Contracts with Customers (Tables)
12 Months Ended
Mar. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [abstract]  
Schedule of Disaggregation of Revenue from Contracts with Customers

The principal activities of the Company for the years ended March 31, 2022 and 2021 were as follows:

 

 

 

For the Year Ended March 31,

 

Revenue categories

 

2022

 

 

2021

 

ViraxClear and ViraxCare

 

 

 

 

 

104,820

 

Consulting revenues

 

 

 

 

 

19,000

 

Total

 

$

 

 

$

123,820